Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill for eczema enters first human tests

NCT ID NCT07558668

Symptom relief Sponsor: Sitryx Therapeutics Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests a new oral drug called SYX-5219 in healthy volunteers and people with moderate to severe atopic dermatitis (eczema). The main goal is to check safety and how the drug moves through the body. About 149 participants will take single or multiple doses over 42 days. It is too early to know if the drug works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SYX-5219 oral capsule
What this could lead to
If successful, this could lead to a new oral treatment option for moderate to severe atopic dermatitis, potentially easing symptoms like itching and inflammation.
What could go wrong
This is a very early Phase 1 trial focused on safety, not yet on effectiveness. The drug may fail to show benefit or cause side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 149 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Parts 1 \& 2 * Healthy male and female participant, between ≥ 18 to ≤ 65 years of age, inclusive, with a BMI of body mass index (BMI) of 18-32 kg/m2. * Female participant of non-childbearing potential or female of childbearing potential that is sexually abstinent. * No clinically significant abnormalities in laboratory, vital signs or ECG measurements. Part 3 * Male and female participants with clinically confirmed diagnosis of active AD, between ≥ 18 to ≤ 65 years of age, inclusive, with a BMI of body mass index (BMI) of ≤40 kg/m2. * Meet minimum AD entry criteria; * AD covering ≥10% of the body surface area (BSA) at screening and baseline. * Eczema Area and Severity Index (EASI) score ≥16 at screening and baseline. * Validated Investigator's Global Assessment (vIGA) score of ≥ 3 (moderate) at screening and baseline. * Peak Pruritus NRS score of ≥ 4 at screening and baseline. Exclusion Criteria: Parts 1 \& 2 • Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 35 days or 5 half-lives (whichever is longer) prior to the first dose of IMP. Part 3 * Any clinically significant medical condition or physical/laboratory/ECG/vital signs abnormality that would, in the opinion of the Investigator, put the participant at undue risk. * Has medical history as stated in the main study exclusion criteria. * Received treatment(s) as stated in the main study exclusion criteria.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Moderate-to-severe atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Moderate-to-severe atopic dermatitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    13 sites in 6 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Sitryx Clinical Site

    RECRUITING

    Arkansas City, Arkansas, 72117, United States

  • Sitryx Clinical Site

    RECRUITING

    Fremont, California, 94538, United States

  • Sitryx Clinical Site

    RECRUITING

    Plainfield, Indiana, 46168, United States

  • Sitryx Clinical Site

    RECRUITING

    Boardman, Ohio, 44512, United States

  • Sitryx Clinical Site

    RECRUITING

    Philadelphia, Pennsylvania, 19103, United States

  • Sitryx Clinical Site

    RECRUITING

    Bountiful, Utah, 84010, United States

  • Sitryx Clinical Site

    RECRUITING

    Sofia, 1404, Bulgaria

  • Sitryx Clinical Site

    NOT_YET_RECRUITING

    Herlev, Herlev, 2730, Denmark

  • Sitryx Clinical Site

    RECRUITING

    Berlin, 10117, Germany

  • Sitryx Clinical Site

    RECRUITING

    Frankfurt, 60596, Germany

  • Sitryx Clinical Site

    ACTIVE_NOT_RECRUITING

    Freiburg im Breisgau, 79106, Germany

  • Sitryx Clinical Site

    RECRUITING

    Dublin, D08 NHY1, Ireland

  • Sitryx Clinical Site

    RECRUITING

    Manchester, M23 9QZ, United Kingdom

  • Sitryx Clinical Site

    RECRUITING

    Merthyr Tydfil, CF48 4DR, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.